… Ribal m , Antoine G. van der Heijden a … High-dose-intensity MVAC combined with G-CSF
is less toxic and has demonstrated a higher CR rate and better 2-yr survival than standard …

… Thalmann m , Antoine G. van der Heijden n , Erik Veskimäe o , J. Alfred Witjes n , Matthew I.
Milowsky p , EAU Muscle-invasive, Metastatic … AG van der Heijden have nothing to declare. …

Bladder cancer is among the ten most common cancers globally, causes considerable
morbidity and mortality and is, therefore, a substantial burden for health-care systems. The …

… Antoine van der Heijden receives company speaker honoraria from Janssen Oncology
and is a company consultant for Ferring, Janssen Oncology, and Janssen Pharmaceuticals. …

Context The European Association of Urology (EAU) guidelines panel on Muscle-invasive
and Metastatic bladder cancer (BCa) updates its guidelines yearly. This updated summary …

Background The European Association of Urology (EAU) prognostic factor risk groups for
non–muscle-invasive bladder cancer (NMIBC) are used to provide recommendations for …

Background Despite adjuvant intravesical therapy, recurrences in non–muscle-invasive
bladder cancer (NMIBC) are still high; therefore, new treatment options are needed. The use of …

… Lam d , James N’Dow d , Antoine G. van der Heijden a , Eva Compérat g , Nigel C. Cowan
h , Maria De Santis i , Georgios Gakis j , Thierry Lebret k , Maria J. Ribal l , Amir Sherif m , J. …

Intravesical BCG instillation is the gold-standard adjuvant immunotherapy for patients with
high-risk non-muscle-invasive bladder cancer. However, the precise mechanism of action by …

Background Although guidelines exist for advanced and variant bladder cancer
management, evidence is limited/conflicting in some areas and the optimal approach remains …